Real-time enrollment status for this her2-positive metastatic breast cancer clinical trial
Current Status
Recruiting
Checked: July 13, 2026 at 8:48 AM UTC
| NCT Number | NCT06551116 |
| Recruiting Status | Recruiting |
| Condition | HER2-positive Metastatic Breast Cancer |
| Phase | Clinical Trial |
| Target Enrollment | 200 participants |
| Active Locations | 37 sites in the US |
| Sponsor | Abramson Cancer Center at Penn Medicine |
| Last Updated on CT.gov | July 8, 2026 (5 days ago) |
As of July 13, 2026: Clinical trial NCT06551116 is currently recruiting participants. This clinical trial study for her2-positive metastatic breast cancer is actively seeking new participants at 37 locations across the United States. The study is sponsored by Abramson Cancer Center at Penn Medicine. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT06551116 is actively recruiting participants as of July 13, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 37 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT06551116 was last updated 5 days ago (July 8, 2026). HelloStudys verifies this status automatically.